Sigma Healthcare Ltd (ASX:SIG) shares have already been battered in the past couple of months, as the company outlined sales challenges.
Sigma closed yesterday at A$0.93, an improvement from the recent 12-month low of A$0.73, but well down from the high of A$1.53 late in 2016 before the problems were known to the market.
The company has today outlined further challenging general industry conditions.
Sigma now anticipates that 1H18 underlying EBIT will be around A$44mln, with FY2018 underlying EBIT expected to be around A$90mln.
This compares to current market consensus for FY18 of circa A$95mln underlying EBIT.
Mark Hooper, CEO and managing director, commented: "Sigma delivered above guidance growth in FY17 and remains confident that our business strategy and increased investment in infrastructure will deliver growth and efficiency improvements beyond the current year."